Precigen Inc (PGEN) - Total Assets
Based on the latest financial reports, Precigen Inc (PGEN) holds total assets worth $156.62 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Precigen Inc's book value for net asset value and shareholders' equity analysis.
Precigen Inc - Total Assets Trend (2011–2025)
This chart illustrates how Precigen Inc's total assets have evolved over time, based on quarterly financial data.
Precigen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Precigen Inc's total assets of $156.62 Million consist of 73.6% current assets and 26.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.3% |
| Accounts Receivable | $4.36 Million | 2.8% |
| Inventory | $9.58 Million | 6.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.18 Million | 2.0% |
| Goodwill | $15.23 Million | 9.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how Precigen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Precigen Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Precigen Inc's current assets represent 73.6% of total assets in 2025, an increase from 20.0% in 2011.
- Cash Position: Cash and equivalents constituted 19.3% of total assets in 2025, up from 17.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 28.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 9.7% of total assets.
Precigen Inc Competitors by Total Assets
Key competitors of Precigen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Precigen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.09 | 4.76 | 5.71 |
| Quick Ratio | 2.83 | 4.76 | 5.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $77.93 Million | $80.90 Million | $118.88 Million |
Precigen Inc - Advanced Valuation Insights
This section examines the relationship between Precigen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 66.69 |
| Latest Market Cap to Assets Ratio | 9.22 |
| Asset Growth Rate (YoY) | 7.8% |
| Total Assets | $156.62 Million |
| Market Capitalization | $1.44 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Precigen Inc's assets at a significant premium (9.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Precigen Inc's assets grew by 7.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Precigen Inc (2011–2025)
The table below shows the annual total assets of Precigen Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $156.62 Million | +7.82% |
| 2024-12-31 | $145.27 Million | -3.82% |
| 2023-12-31 | $151.04 Million | -30.07% |
| 2022-12-31 | $215.98 Million | -39.98% |
| 2021-12-31 | $359.86 Million | +14.39% |
| 2020-12-31 | $314.59 Million | -30.98% |
| 2019-12-31 | $455.76 Million | -36.36% |
| 2018-12-31 | $716.18 Million | -15.43% |
| 2017-12-31 | $846.85 Million | -10.77% |
| 2016-12-31 | $949.07 Million | -3.36% |
| 2015-12-31 | $982.05 Million | +70.41% |
| 2014-12-31 | $576.27 Million | +22.75% |
| 2013-12-31 | $469.47 Million | +209.58% |
| 2012-12-31 | $151.65 Million | +32.06% |
| 2011-12-31 | $114.83 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more